Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has released its interim report for the first half of 2026, revealing a complex financial picture. The company recorded operating revenue of RMB 42.091 billion for the period, a modest year-on-year increase of 0.61%, yet net profit attributable to shareholders fell sharply by 16.70% to RMB 2.096 billion. After deducting non-recurring gains and losses, net profit stood at RMB 1.939 billion, representing a 12.10% decline from the prior year.

On a quarterly basis, the second quarter painted an even more challenging picture, with revenue declining 2.83% year-on-year to RMB 18.813 billion. More strikingly, single-quarter net profit attributable to shareholders plummeted by 55.07% to just RMB 312 million, while adjusted net profit dropped by 55.69%. As a leading pharmaceutical conglomerate in South China and a dominant force in the herbal tea category, Baiyunshan is confronting multiple headwinds, including plateauing growth in its traditional businesses, shrinking profit margins, and a gradual deterioration in overall financial quality.

Pharmaceutical Distribution Alone Drives Revenue While Core Segments Weaken Across the Board

Baiyunshan's business portfolio spans four main segments: modern Chinese medicine, chemical pharmaceuticals, natural beverages, and pharmaceutical distribution, supplemented by emerging ventures in biotech innovation, consumer health, and medical services. The 2026 interim data shows continued expansion in the low-margin distribution segment, while all three high-margin core segments contracted, dragging the company's overall gross margin lower.

Specifically, the pharmaceutical distribution segment generated RMB 29.936 billion in revenue during the first half, up 6.03% year-on-year, representing over 71% of total revenue and marking it as the only main business segment to achieve positive growth. However, this segment carries a razor-thin gross margin of just 5.95%, contributing minimally to overall profitability. In contrast, the other three high-margin segments all saw declines: modern Chinese medicine revenue fell 11.06% to RMB 3.891 billion, chemical pharmaceuticals dropped 15.91% to RMB 1.106 billion, and the natural beverages segment, anchored by the Wanglaoji brand, slipped 12.40% to RMB 6.157 billion.

The shift toward low-margin activities at the expense of high-margin ones has considerably eroded the company's profitability. In the first half of 2026, Baiyunshan's consolidated gross margin fell to 17.27%, down 1.05 percentage points year-on-year, while its net margin dropped 1.03 percentage points to 5.13%. Both metrics have reached historical lows.

Looking at the core profit center, Wanglaoji's large health segment saw its first-half revenue decline from RMB 6.499 billion in the same period last year to RMB 5.615 billion, with net profit falling from RMB 1.295 billion to RMB 933 million, a year-on-year decrease of approximately 28%. Amid an aging consumer base, younger demographics gravitating toward more diverse beverage options, and intensifying competitive pressures, the herbal tea category has edged closer to its growth ceiling after years of rapid expansion. The fundamentals of the Wanglaoji brand remain under significant strain. While the company has been introducing new products, such as electrolyte drinks, in an attempt to cultivate a second growth curve, the current scale of these new offerings is insufficient to fill the void left by stagnating traditional herbal tea sales.

The pharmaceutical segment is also grappling with growth difficulties. According to the 2025 annual report, core products, including sildenafil citrate tablets (marketed as Jinge), Xiaochaihu granules, Zishen Yutai pills, Aka Phenol series, and cefuroxime sodium for injection, all recorded declining sales. Notably, Xiaochaihu granules and cefuroxime sodium for injection both experienced double-digit volume drops, falling 19.59% and 25.85%, respectively. Additionally, the fourth batch of national centralized procurement for Chinese patent medicines commenced bidding in May 2026, covering 89 commonly used clinical drugs, with over-the-counter medications included on a large scale for the first time. This development could subject numerous household medicine products from Baiyunshan to renewed pricing pressure.

Legal Dispute Over Jinge Resurfaces Amid Unresolved Compliance Concerns

Beyond financial and operational risks, governance issues and legal entanglements warrant close attention. Since the beginning of 2026, a long-standing dispute surrounding the Jinge product has reignited. In 1999, Baiyunshan entered into a joint venture agreement with Beijing Kangyeyuan Investment Consulting Co., Ltd. The following year, in June 2000, Baiyunshan Technology was formally incorporated. Kangyeyuan contributed R&D achievements, including the clinical approval for Jinge, in exchange for a 49% stake, while Baiyunshan held 51%, contributing assets such as trademark usage rights.

Upon its launch, Jinge quickly became a blockbuster product, generating over RMB 2 billion in sales and exceeding RMB 1 billion in profits within four years. However, the minority shareholder Kangyeyuan has alleged that its rights to information access and dividend distribution have long gone unrealized. In 2019, the firm publicly accused Baiyunshan of inflating raw material costs, unfair profit distribution, and benefit transfers. Baiyunshan responded by suing Kangyeyuan for reputational infringement. After trials at two levels of court, the judiciary ultimately ruled that Kangyeyuan had committed reputational infringement, requiring it to issue an apology and pay RMB 150,000 in damages.

The situation took a pivotal turn in 2022. The National Healthcare Security Administration announced that it had verified that three subsidiaries of Baiyunshan had artificially inflated active pharmaceutical ingredient prices and diverted funds between 2017 and May 2021, with some funds used for improper promotional activities. The modus operandi closely resembled the allegations made by Kangyeyuan years earlier. In May 2025, Li Chuyuan, the former chairman of the parent company Guangzhou Pharmaceutical Holdings, was expelled from the Party and dismissed from his post for serious disciplinary and legal violations.

Subsequently, in March 2026, Kangyeyuan filed a civil retrial application with the Guangzhou Intermediate People's Court, citing new evidence and requesting the original judgment be overturned and the case reopened. Concurrently, Kangyeyuan reported to the China Securities Regulatory Commission and the Shanghai Stock Exchange that Baiyunshan's information disclosure was incomplete and potentially contained misleading statements. The firm also initiated administrative litigation concerning the National Healthcare Security Administration's public information disclosures. On April 17, 2026, the National Healthcare Security Administration responded that two items involved state secrets and would not be disclosed, while three other items fell outside its jurisdiction. Dissatisfied with this response, Kangyeyuan filed for administrative reconsideration on June 5, 2026, and on July 9, the administration upheld its original decision.

On July 16, 2026, Kangyeyuan formally submitted an administrative complaint against both the Government Information Disclosure Reply and the Administrative Reconsideration Decision issued by the National Healthcare Security Administration. The case is currently awaiting a court hearing date.